Company profile

Scinai Immunotherapeutics Ltd.

Pipeline3 assets

PC111PC111 / sFasL (soluble Fas Ligand) / Monoclonal Antibody / Immunology / Dermatology
PemphigusPreclinicalActiveGlobalStevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN)PreclinicalActiveGlobal
Intradermal IL-17A/F NanoAbIL-17A / IL-17F / VHH Antibody Fragment (NanoAb) / Immunology / Dermatology
Mild-to-moderate plaque psoriasisPreclinicalActiveGlobal
Systemic Bi-Specific IL-17 NanoAbIL-17A / IL-17F and secondary proprietary target / Bi-specific VHH Antibody Fragment (NanoAb) / Immunology / Dermatology
Moderate-to-severe plaque psoriasisPreclinicalActiveGlobalPsoriatic arthritisPreclinicalActiveGlobal

Latest news8 items

Sep 21, 2026

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

‍ ‍ ‍ Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed ‍ ‍ JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq:...

Sep 8, 2026

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

‍ ‍ ‍ Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments ‍ ‍ JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq:...

Aug 24, 2026

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

‍ ‍ Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum ‍ ‍‍ ‍ Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT ‍ ‍ JERUSALEM, August 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq:...

Aug 11, 2026

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

JERUSALEM, Aug. 10, 2026 /PRNewswire/ Scinai Immunotherapeutics Ltd. (NASDAQ: SC NI ) ("Scinai" or t he "Company" ), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd ....

Jun 10, 2026

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update....

May 20, 2026

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), (“Scinai” or the “Company”), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization...

May 15, 2026

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week...

Apr 24, 2026

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

JERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd ., a contract development and manufacturing organization (CDMO), today announced that it...